Equities research analysts expect that Halozyme Therapeutics, Inc. (NASDAQ:HALO) will report earnings of $0.61 per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Halozyme Therapeutics’ earnings, with the lowest EPS estimate coming in at $0.53 and the highest estimate coming in at $0.73. Halozyme Therapeutics reported earnings of ($0.21) per share during the same quarter last year, which would indicate a positive year over year growth rate of 390.5%. The business is expected to report its next quarterly earnings results on Tuesday, February 27th.
On average, analysts expect that Halozyme Therapeutics will report full year earnings of $0.20 per share for the current fiscal year, with EPS estimates ranging from $0.06 to $0.36. For the next year, analysts anticipate that the business will report earnings of ($0.73) per share, with EPS estimates ranging from ($1.07) to ($0.45). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Halozyme Therapeutics.
Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.04). The firm had revenue of $63.73 million for the quarter, compared to the consensus estimate of $58.95 million. Halozyme Therapeutics had a negative net margin of 53.17% and a negative return on equity of 892.57%. The business’s revenue for the quarter was up 100.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.23) earnings per share.
A number of brokerages have weighed in on HALO. BidaskClub cut Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th. Zacks Investment Research cut Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, December 25th. Barclays cut Halozyme Therapeutics from an “overweight” rating to a “hold” rating and upped their price target for the company from $16.00 to $19.00 in a research report on Wednesday, November 22nd. Canaccord Genuity upped their price target on Halozyme Therapeutics from $17.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, November 8th. Finally, BMO Capital Markets upped their price target on Halozyme Therapeutics from $15.00 to $18.00 and gave the company a “market perform” rating in a research report on Wednesday, November 8th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the company’s stock. Halozyme Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $19.14.
Shares of Halozyme Therapeutics (NASDAQ:HALO) traded up $0.13 during trading hours on Wednesday, reaching $17.98. The company’s stock had a trading volume of 1,360,000 shares, compared to its average volume of 1,380,000. Halozyme Therapeutics has a 52-week low of $10.79 and a 52-week high of $21.13. The company has a market capitalization of $2,570.00, a PE ratio of -26.44 and a beta of 2.09. The company has a quick ratio of 3.37, a current ratio of 3.46 and a debt-to-equity ratio of 2.01.
Large investors have recently made changes to their positions in the business. The Manufacturers Life Insurance Company boosted its stake in Halozyme Therapeutics by 524.7% in the second quarter. The Manufacturers Life Insurance Company now owns 1,011,449 shares of the biopharmaceutical company’s stock worth $12,968,000 after purchasing an additional 849,545 shares in the last quarter. Vanguard Group Inc. boosted its stake in Halozyme Therapeutics by 9.5% in the second quarter. Vanguard Group Inc. now owns 9,595,212 shares of the biopharmaceutical company’s stock worth $123,010,000 after purchasing an additional 831,654 shares in the last quarter. Senzar Asset Management LLC boosted its stake in Halozyme Therapeutics by 17.1% in the second quarter. Senzar Asset Management LLC now owns 4,087,264 shares of the biopharmaceutical company’s stock worth $52,399,000 after purchasing an additional 597,400 shares in the last quarter. BlackRock Inc. boosted its stake in Halozyme Therapeutics by 4.8% in the second quarter. BlackRock Inc. now owns 11,595,500 shares of the biopharmaceutical company’s stock worth $148,652,000 after purchasing an additional 532,658 shares in the last quarter. Finally, BB Biotech AG boosted its stake in Halozyme Therapeutics by 6.7% in the second quarter. BB Biotech AG now owns 8,265,304 shares of the biopharmaceutical company’s stock worth $105,961,000 after purchasing an additional 515,472 shares in the last quarter. Hedge funds and other institutional investors own 84.45% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/20/zacks-brokerages-anticipate-halozyme-therapeutics-inc-halo-to-announce-0-61-eps.html.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Get a free copy of the Zacks research report on Halozyme Therapeutics (HALO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.